JPMorgan Chase & Co. lowered its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,305 shares of the company's stock after selling 576,747 shares during the quarter. JPMorgan Chase & Co.'s holdings in Ginkgo Bioworks were worth $125,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Ginkgo Bioworks by 644.5% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 32,319 shares of the company's stock worth $263,000 after purchasing an additional 27,978 shares in the last quarter. Verition Fund Management LLC acquired a new stake in Ginkgo Bioworks in the third quarter worth about $792,000. Algert Global LLC purchased a new stake in shares of Ginkgo Bioworks during the second quarter worth about $36,000. Forbes J M & Co. LLP purchased a new position in shares of Ginkgo Bioworks in the 3rd quarter valued at approximately $1,019,000. Finally, PDT Partners LLC purchased a new stake in Ginkgo Bioworks during the 3rd quarter worth approximately $1,199,000. 78.63% of the stock is currently owned by hedge funds and other institutional investors.
Ginkgo Bioworks Price Performance
Shares of NYSE:DNA traded down $2.72 on Thursday, hitting $13.64. 3,913,727 shares of the company were exchanged, compared to its average volume of 1,541,036. The stock has a 50 day moving average price of $10.73. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $5.26 and a 1-year high of $64.40. The stock has a market cap of $783.91 million, a price-to-earnings ratio of -1.04 and a beta of 1.16.
Ginkgo Bioworks Profile
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Further Reading
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
